

Dengue Vaccine Market - Global Industry Forecast – 2025

WiseGuyReports.com Presents "Global Dengue Vaccine Market Research Report 2019" New Document to its Studies Database

PUNE, INDIA, March 11, 2019
/EINPresswire.com/ --

The *Aedes aegypti* mosquito is responsible for transmitting the dengue virus (DENV). The virus that causes dengue belongs to the Flavivirus genus of the Flaviviridae family. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. However, dengue hemorrhagic fever is a potentially fatal complication because of multiple factors such as fluid accumulation, severe bleeding, organ impairment, or plasma leaking.

With the increasing population density and global warming, there is a rapid growth in the prevalence of dengue, especially in the tropical and subtropical regions across the world. According to the National Institute of Health, approximately 0.05 to 0.2 billion cases of dengue infections are reported annually and the mortality rate due to dengue was above 20,000. The report has identified the rapid growth in disease incidences as one of the primary factors that will fuel the growth of the [dengue vaccine](#) market in the coming years. The prevalence of dengue is present in more than 125 countries across the world and the rising prevalence of dengue will drive the market during the forecast period.

The dengue vaccine market is marginally concentrated due to the presence and dominance of the established players. Several companies are investing in R&D to develop more advanced products and expand their product portfolio. Several organizations are merging for research and making enormous efforts to develop vaccines that can challenge the Sanofi Pasteur's exclusivity in the dengue treatment market. Moreover, several organizations are making huge investments in R&D to develop novel treatment options.

The Americas will be the major revenue contributor to the dengue vaccine market owing to the increasing incidences of dengue cases. The dengue treatment market in the Americas will profit from the bilateral program, Indo-U.S. Vaccine Action Program (VAP), which is concentrated on activities related to immunization and vaccine-related research.

The global Dengue Vaccine market is valued at xx million US\$ in 2018 is expected to reach xx million US\$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.

This report focuses on Dengue Vaccine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dengue Vaccine market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

The following manufacturers are covered:

GlaxoSmithKline
Merck Sharp & Dohme
Sanofi
Takeda Pharmaceuticals
GeneOne Life Sciences
Medigen Biologics
Panacea Biotec
Sun Pharmaceutical
U.S NIH
Vabiotec

Request Free Sample Report @ <https://www.wiseguyreports.com/sample-request/3803270-global-dengue-vaccine-market-research-report-2019>

Segment by Regions

North America
Europe
China
Japan

Segment by Type

CYD-TDV
DENVax or TAK-003
TetraVax-DV
TDENV PIV
V180
DNA vaccines

Segment by Application

Government institutions
Hospitals
NGOs

Complete Report Details @ <https://www.wiseguyreports.com/reports/3803270-global-dengue-vaccine-market-research-report-2019>

Table Of Contents:

1 Dengue Vaccine Market Overview
1.1 Product Overview and Scope of Dengue Vaccine
1.2 Dengue Vaccine Segment by Type
1.2.1 Global Dengue Vaccine Production Growth Rate Comparison by Type (2014-2025)
1.2.2 CYD-TDV
1.2.3 DENVax or TAK-003
1.2.4 TetraVax-DV
1.2.5 TDENV PIV

- 1.2.6 V180
- 1.2.7 DNA vaccines
- 1.3 Dengue Vaccine Segment by Application
 - 1.3.1 Dengue Vaccine Consumption Comparison by Application (2014-2025)
 - 1.3.2 Government institutions
 - 1.3.3 Hospitals
 - 1.3.4 NGOs
- 1.4 Global Dengue Vaccine Market by Region
 - 1.4.1 Global Dengue Vaccine Market Size Region
 - 1.4.2 North America Status and Prospect (2014-2025)
 - 1.4.3 Europe Status and Prospect (2014-2025)
 - 1.4.4 China Status and Prospect (2014-2025)
 - 1.4.5 Japan Status and Prospect (2014-2025)
- 1.5 Global Dengue Vaccine Market Size
 - 1.5.1 Global Dengue Vaccine Revenue (2014-2025)
 - 1.5.2 Global Dengue Vaccine Production (2014-2025)

- 2 Global Dengue Vaccine Market Competition by Manufacturers
 - 2.1 Global Dengue Vaccine Production Market Share by Manufacturers (2014-2019)
 - 2.2 Global Dengue Vaccine Revenue Share by Manufacturers (2014-2019)
 - 2.3 Global Dengue Vaccine Average Price by Manufacturers (2014-2019)
 - 2.4 Manufacturers Dengue Vaccine Production Sites, Area Served, Product Types
 - 2.5 Dengue Vaccine Market Competitive Situation and Trends
 - 2.5.1 Dengue Vaccine Market Concentration Rate
 - 2.5.2 Dengue Vaccine Market Share of Top 3 and Top 5 Manufacturers
 - 2.5.3 Mergers & Acquisitions, Expansion

...

- 7 Company Profiles and Key Figures in Dengue Vaccine Business
 - 7.1 GlaxoSmithKline
 - 7.1.1 GlaxoSmithKline Dengue Vaccine Production Sites and Area Served
 - 7.1.2 Dengue Vaccine Product Introduction, Application and Specification
 - 7.1.3 GlaxoSmithKline Dengue Vaccine Production, Revenue, Price and Gross Margin (2014-2019)
 - 7.1.4 Main Business and Markets Served
 - 7.2 Merck Sharp & Dohme
 - 7.2.1 Merck Sharp & Dohme Dengue Vaccine Production Sites and Area Served
 - 7.2.2 Dengue Vaccine Product Introduction, Application and Specification
 - 7.2.3 Merck Sharp & Dohme Dengue Vaccine Production, Revenue, Price and Gross Margin (2014-2019)
 - 7.2.4 Main Business and Markets Served
 - 7.3 Sanofi
 - 7.3.1 Sanofi Dengue Vaccine Production Sites and Area Served
 - 7.3.2 Dengue Vaccine Product Introduction, Application and Specification
 - 7.3.3 Sanofi Dengue Vaccine Production, Revenue, Price and Gross Margin (2014-2019)
 - 7.3.4 Main Business and Markets Served
 - 7.4 Takeda Pharmaceuticals
 - 7.4.1 Takeda Pharmaceuticals Dengue Vaccine Production Sites and Area Served
 - 7.4.2 Dengue Vaccine Product Introduction, Application and Specification
 - 7.4.3 Takeda Pharmaceuticals Dengue Vaccine Production, Revenue, Price and Gross Margin (2014-2019)
 - 7.4.4 Main Business and Markets Served
 - 7.5 GeneOne Life Sciences
 - 7.5.1 GeneOne Life Sciences Dengue Vaccine Production Sites and Area Served
 - 7.5.2 Dengue Vaccine Product Introduction, Application and Specification

7.5.3 GeneOne Life Sciences Dengue Vaccine Production, Revenue, Price and Gross Margin (2014-2019)

7.5.4 Main Business and Markets Served

Continued.....

CONTACT US:

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
646 845 9349 / +44 208 133 9349
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.